News Releases

15 Mar '22
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 15, 2022-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Marwan Noel
14 Mar '22
New data expands evidence base of role of P. gingivalis in Alzheimer’s disease Discussion to include new biomarker results   and correlations between biomarkers and clinical outcomes SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 14, 2022-- Cortexyme, Inc.
01 Feb '22
Next generation lysine gingipain inhibitor COR588 with novel structure and improved pharmacologic and safety profile prioritized for Alzheimer’s development Additional pipeline includes therapeutics in development for coronavirus infection, periodontal disease, and prevention of oral squamous cell
01 Feb '22
Christopher Lowe appointed interim chief executive officer David Lamond named chairman of the board SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 1, 2022-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, today
Displaying 11 - 18 of 18